ATC code B01
Drug classification – antithrombotic agents
Pharmaceutical drug classification
ATC code B: Blood and blood forming organs |
---|
|
Other ATC codes |
ATC code B01 Antithrombotic agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup B01 is part of the anatomical group B Blood and blood forming organs.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QB01.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
B01A Antithrombotic agents
B01AA Vitamin K antagonists
- B01AA01 Dicoumarol
- B01AA02 Phenindione
- B01AA03 Warfarin
- B01AA04 Phenprocoumon
- B01AA07 Acenocoumarol
- B01AA08 Ethyl biscoumacetate
- B01AA09 Clorindione
- B01AA10 Diphenadione
- B01AA11 Tioclomarol
- B01AA12 Fluindione
B01AB Heparin group
- B01AB01 Heparin
- B01AB02 Antithrombin III
- B01AB04 Dalteparin
- B01AB05 Enoxaparin
- B01AB06 Nadroparin
- B01AB07 Parnaparin
- B01AB08 Reviparin
- B01AB09 Danaparoid
- B01AB10 Tinzaparin
- B01AB11 Sulodexide
- B01AB12 Bemiparin
- B01AB51 Heparin, combinations
B01AC Platelet aggregation inhibitors excluding heparin
- B01AC01 Ditazole
- B01AC02 Cloricromen
- B01AC03 Picotamide
- B01AC04 Clopidogrel
- B01AC05 Ticlopidine
- B01AC06 Acetylsalicylic acid
- B01AC07 Dipyridamole
- B01AC08 Carbasalate calcium
- B01AC09 Epoprostenol
- B01AC10 Indobufen
- B01AC11 Iloprost
- B01AC13 Abciximab
- B01AC15 Aloxiprin
- B01AC16 Eptifibatide
- B01AC17 Tirofiban
- B01AC18 Triflusal
- B01AC19 Beraprost
- B01AC21 Treprostinil
- B01AC22 Prasugrel
- B01AC23 Cilostazol
- B01AC24 Ticagrelor
- B01AC25 Cangrelor
- B01AC26 Vorapaxar
- B01AC27 Selexipag
- B01AC28 Limaprost
- B01AC30 Combinations
- B01AC56 Acetylsalicylic acid, combinations with proton pump inhibitors
B01AD Enzymes
- B01AD01 Streptokinase
- B01AD02 Alteplase
- B01AD03 Anistreplase
- B01AD04 Urokinase
- B01AD05 Fibrinolysin
- B01AD06 Brinase
- B01AD07 Reteplase
- B01AD08 Saruplase
- B01AD09 Ancrod
- B01AD10 Drotrecogin alfa (activated)
- B01AD11 Tenecteplase
- B01AD12 Protein C
- B01AD13 Apadamtase alfa and cinaxadamtase alfa
- B01AE01 Desirudin
- B01AE02 Lepirudin
- B01AE03 Argatroban
- B01AE04 Melagatran
- B01AE05 Ximelagatran
- B01AE06 Bivalirudin
- B01AE07 Dabigatran etexilate
- B01AF01 Rivaroxaban
- B01AF02 Apixaban
- B01AF03 Edoxaban
- B01AF04 Betrixaban
- B01AF51 Rivaroxaban and acetylsalicylic acid
B01AX Other antithrombotic agents
- B01AX01 Defibrotide
- B01AX04 Dermatan sulfate
- B01AX05 Fondaparinux
- B01AX07 Caplacizumab
References
- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code B01". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QB01". WHO Collaborating Centre for Drug Statistics Methodology.
- v
- t
- e
Glycoprotein IIb/IIIa inhibitors |
|
---|---|
ADP receptor/P2Y12 inhibitors | |
Prostaglandin analogue (PGI2) | |
COX inhibitors | |
Thromboxane inhibitors | |
Phosphodiesterase inhibitors | |
Other |
Vitamin K antagonists (inhibit II, VII, IX, X) | |||||
---|---|---|---|---|---|
Factor Xa inhibitors (with some II inhibition) |
| ||||
Direct thrombin (IIa) inhibitors |
| ||||
Other |
fibrinolytics
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III